SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

SIGA Technologies, Inc.NASDAQ: SIGA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $740.38K (cash outflow) rose 345.5% year over year, ahead of the +1.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 743.0% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.

Context

  • Financing cash flow amounted to 46.0% of revenue in FY2025, up 14.7 pp from a year earlier.
  • Financing cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +345.5% holds above the trailing-twelve-month pace of +1.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$740.38K+743.0% QoQ
Last fiscal yearDec 2025
-$43.55M+0.2% YoY
LTMMar 2026
-$44.12M+1.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+345.5%——
1 year+0.2%——
3-year CAGR-1.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(43.55M) USD
Year-over-year change
-0.2%

Financing Cash Flow vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.5% is the 5th highest of 10, against a peer median of -1.3%.
  • Financing cash flow amounts to 47.0% of revenue for SIGA, versus a peer median of 18.1%.
SIGA Competitors
Financing Cash Flow for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$344.93M USD+4594.2%+454.4%970.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$256.78M USD-1.3%+662.8%—
EBSEmergent BioSolutions Inc.LTM Mar 2026$147.6M USD-36.1%—21.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$86.39M USD+284.0%+107.0%171.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$59.9M USD+615.4%+3.5%14.3%
SNDLSNDL Inc.LTM Mar 2026CA$50.85M CAD-20.7%+9.2%5.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$44.12M USD+1.5%-1.8%47.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$35.52M USD-226.0%+99.1%6.9%
DRIODarioHealth Corp.LTM Mar 2026$17.5M USD-30.4%-26.8%82.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$10.8M USD+25.0%-54.9%3.6%
Peer median (excluding SIGA) —-1.3%+54.2%18.1%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income69.45M33.9M68.07M59.21M23.28M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
Deferred Income Tax121.45K(3.83M)(4.8M)193.42K6.43M
Stock-Based Compensation1.27M1.78M2.05M3.64M3.68M
Change in Working Capital(60.37M)9.44M28.36M(4.69M)8.26M
Accounts Receivables(80.31M)38.24M24.28M(35.18K)17.9M
Inventory136.37K(19.96M)(25.52M)15.34M(846.31K)
Accounts Payables1.47M2.07M2M(5.74M)(578.64K)
Other Working Capital18.34M(10.91M)27.61M(14.26M)(8.22M)
Other Non-Cash Items501K(199.19K)579.24K(10.13M)1.26M
Operating Cash Flow11.49M41.61M94.8M48.76M43.47M
Capital Expenditures(50.62K)0(21.69K)(42.45K)(355.01K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(50.62K)0(21.69K)(42.45K)(355.01K)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased(26.02M)(13.01M)(11.07M)(799.9K)0
Dividends Paid0(32.94M)(32.14M)(42.67M)(43.12M)
Other Financing Activities(173.92K)(12.53K)(214.79K)0(433.76K)
Financing Cash Flow(26.2M)(45.96M)(43.42M)(43.46M)(43.55M)
Effect of Forex Changes00000
Net Change in Cash(14.75M)(4.35M)51.36M5.25M(433.85K)
Free Cash Flow11.44M41.61M94.78M48.72M43.12M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.